Company / Gross Margin
Sonoma Pharmaceuticals, Inc. Gross Margin History
FY2017-FY2026 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
38.3%
FY2026
5-year range
31.6% / 38.3%
FY2022-FY2026
Trend
+2.7%
vs FY2025
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Gross Margin has increased for 3 consecutive years, from 31.6% in FY2023 to 38.3% in FY2026.
Based on SEC 10-K filings.
38.3% in FY2026 with a 5-year CAGR of -7.1%.
Improved from 33.7% to 38.3% over the past 2 years.
Gross Margin over time
Growth rates
- 3-Year Change
- +6.6pp
- 5-Year Change
- -7.1pp
- 10-Year Change
- -
Key checks
Key Insights
- Sonoma Pharmaceuticals, Inc.'s gross margin has grown for 3 consecutive years.
- In FY2026, gross margin increased 2.7% year-over-year.
- Peak gross margin was recorded in FY2020.
- Lowest gross margin in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | 38.3% | +2.7% |
| FY2025 | 37.3% | +10.5% |
| FY2024 | 33.7% | +6.7% |
| FY2023 | 31.6% | -10.2% |
| FY2022 | 35.2% | -22.3% |
| FY2021 | 45.3% | -3.2% |
| FY2020 | 46.8% | +6.7% |
| FY2019 | 43.9% | -0.7% |
| FY2018 | 44.2% | +56.4% |
| FY2017 | 28.3% | -46.3% |
As of FY2026 · SEC 10-K · Updated Jun 28, 2026